Fig. 4

Kaplan-Meier estimates of PFS in subgroups treated with olaparib and niraparib, categorized by the presence or absence of BRCA1/2 mutations. (A) Kaplan-Meier plot of PFS in the olaparib subgroups, distinguishing between patients with BRCA1/2 mutations and those with wild-type BRCA1/2. (B) Kaplan-Meier plot of PFS in the niraparib subgroups, stratified by patients with BRCA1/2 mutations and those with wild-type BRCA1/2. (C) Kaplan-Meier plot of PFS in the olaparib and niraparib subgroups specifically among patients with BRCA 1/2 mutations. (D) Kaplan-Meier plot of PFS in the olaparib and niraparib subgroups among patients with wild-type BRCA 1/2